%0 Journal Article
%A Berger, Anne Katrin
%A Lücke, Stephan
%A Abel, Ulrich
%A Haag, Georg Martin
%A Grüllich, Carsten
%A Stange, Annika
%A Dietrich, Mareike
%A Apostolidis, Leonidas
%A Freitag, Angelika
%A Trierweiler, Claudia
%A von Gall, Carl
%A Ose, Jennifer
%A Giesel, Frederik
%A Weber, Tim Frederik
%A Lordick, Florian
%A Haberkorn, Uwe
%A Jäger, Dirk
%T Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
%J British journal of cancer
%V 119
%N 2
%@ 1532-1827
%C Edinburgh
%I Nature Publ. Group
%M DKFZ-2018-01129
%P 170 - 175
%D 2018
%X To assess the predictive value of early metabolic response (ΔSUV) after short-term treatment with first-line cetuximab in patients (pts) with RAS-wt metastatic colorectal cancer (mCRC).In this prospective phase II study, RAS-wt mCRC pts received a single-agent cetuximab run-in therapy of 2 weeks. ΔSUV was assessed with FDG-PET/CT on days 0 and 14. Early clinical response (ECR) was evaluated with CT on day 56 after treatment with FOLFIRI-cetuximab. Primary endpoint was the predictive significance of ΔSUV for ECR. Secondary endpoints were PFS (progression free survival), OS and the influence of ΔSUV on survival.Forty pts were enroled and 33 pts were evaluable for the primary endpoint. The CT response rate was 57.6
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:29961759
%R 10.1038/s41416-018-0152-4
%U https://inrepo02.dkfz.de/record/136660